Spinal Muscular Atrophy (SMA) — Deal Benchmarks & Valuation
Market Analysis
Spinal Muscular Atrophy (SMA) is one of the most actively transacted indications in rare disease licensing. Phase 2 deals for spinal muscular atrophy (sma) carry a median total deal value of $2.0B, with upfront payments ranging from $176M to $553M. The recommended deal structure allocates approximately 18% to upfront payments and 82% to milestones.
Milestone structures for spinal muscular atrophy (sma) deals allocate $361M to development milestones, $411M to regulatory milestones, and $871M to commercial milestones. Royalty rates range from 8.4% to 16.8% at the base tier, with tiered escalation reaching 12.4%-20.8% on peak sales.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for spinal muscular atrophy (sma) licensing?
What royalty rates are standard for spinal muscular atrophy (sma) deals?
How are spinal muscular atrophy (sma) deal milestones structured?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.